Overview

Remifentanil in Extracorporeal Shock Wave Lithotripsy

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the analgesic efficacy and side effects induced by administration of two different infusion rates of remifentanil, 0,05 mcg/ Kg/ min versus 0,1mcg/ Kg/ min, in order to determine which one is the most appropriate analgesic treatment to face extracorporeal shock wave lithotripsy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Roma La Sapienza
Treatments:
Remifentanil
Criteria
Inclusion Criteria:

- ASA (American Society of anaesthesiology) physical status between the I and class II

- Body mass index (BMI) between 18 and 30.

Exclusion Criteria:

- Patients who were unable to give informed consent or with diagnosis of depression

- Concurrent treatment with antidepressant

- Anxiolytic or with opioids or with history of abuse and dependence from these
substances

- Allergy or intolerance to drugs administered in this study

- Severe cognitive deficits or psychiatric disorders

- Liver or renal impairment (aspartate aminotransferase > 40 UI/L alanine
aminotransferase > 40 UI/L, creatinine > 2mg/dL)

- Abnormal values of coagulation (International normalized ratio > 1,2), platelet(<
100.000/µL), arrhythmias and / or defect of atrioventricular conduction.